
    
      Eligible patients will be randomized to receive clopidogrel 600mg + aspirin 325mg (Group A)
      or clopidogrel 600mg + aspirin 81mg (Group B). Patients will be fasted for at least 8 hours
      prior to study drug administration. Blood samples will be collected at 1 hour after study
      drug administration for measurement of clopidogrel active metabolite levels and genotyping.
    
  